Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

Summary

One hundred twenty healthy participants, ages 21 to 70, who experience moderate-to-lower-than-average mental well-being will be evenly randomized into four different study arms, using a 2x2 factorial design. Depending on the study arm, participants will either receive an inactive placebo or up to 25mg psilocybin (oral dose), in one of two set and setting conditions; drug administration contexts that are predicted to modulate drug effects. The purpose of this study is to evaluate any interaction effects between an oral dose of psilocybin and the surrounding context (set and setting).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Healthy Participants With Lower-than-average Mental Well-being

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

21 to 70 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Robin Carhart-Harris, PhD, MA

Last updated on ClinicalTrials.gov

June 4, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites